Antiplatelet

Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel

-- Portola to Receive $75 Million Upfront Cash Payment, $500 Million in Potential Milestone Payments Plus Royalties on Future Sales -- SOUTH SAN FRANCISCO, Calif., Feb. 12 /PRNewswire/ -- Portola Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing innovative drugs tha...

Medicines Used In Antiplatelet Therapy Can Reduce Heart Attacks And Strokes

Research shows that using antiplatelet medication called clopidogrel before coronary angioplasty surgery often reduces the risk of death from cardiovascular problems like heart attacks, or strokes.// The research paper was published in the latest issue of JAMA. Dual antiplatelet therapy follow...

Effient(TM) is Now Available in Pharmacies

...ire-FirstCall/ -- Effient(TM) (prasugrel), a new antiplatelet medicine, is now available in pharmacies across th...was available, physicians and patients had limited antiplatelet therapy options. Effient is a new treatment option... Important Safety Information about Effient antiplatelet medicines, including Effient, can increase the ris...

Accumetrics' VerifyNow(R) P2Y12 Test Provides Physicians With Information to Assess a Patient's Response to Newly-Approved Prasugrel (Effient(R))

...ine the response of an individual patient to their antiplatelet therapy, regardless of the P2Y12 inhibitor that is...rcutaneous coronary intervention and receiving the antiplatelet therapy that follows. In having this alternative t...tion of the therapy that best achieves the desired antiplatelet effect." Accumetrics' VerifyNow P2Y12 Tes...

Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient(TM)

...by drugs that inhibit CYP2C19, including certain proton pump inhibitors such as omeprazole.(iv,v) Important Safety Information about Effient antiplatelet medicines, including Effient, can increase the risk of bleeding. If patients have unexplained or excessive bleeding while on Effient, they should con...

Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress

...ss in Boston that will feature its investigational antiplatelet drug elinogrel, a P2Y(12) ADP receptor antagonist ...104 ABC, Platelets and Systemic Disorders The antiplatelet Effect of a New, Direct Acting, Reversible P2Y12 I...ocation: Poster Area, Patient Oriented Studies of antiplatelet Therapy ADP-Mediated Aggregation as...

Analysis of drug-eluting stents data demonstrates safety, efficacy in on-and-off-label use

...ounding variables," said Dr. Stone. "These data are reassuring that DES are safe and effective for a wide-range of patients that are able to take dual antiplatelet therapy for at least one year." The findings were consistent and robust across a variety of study designs; trials that were included were required ...

Accumetrics, Inc. Announces Distribution Channels in Israel and Cyprus

.... The VerifyNow System assesses response to antiplatelet therapies, such as aspirin, Plavix(R) and GP IIb/I...the tests help physicians ensure their patients on antiplatelet medications are receiving the optimal benefit. ...tion for managing their cardiovascular patients on antiplatelet therapies." About Accumetrics ( www.accu...

Daiichi Sankyo, Inc. Celebrates the Growth of Its U.S. Headquarters

... diabetes, and in anticipation of the continuing development of its robust pipeline of compounds for cardiovascular disease and oncology, including an antiplatelet agent currently under FDA review. According to a 2008 report by the HealthCare Institute of New Jersey, drug industry employment in the state dro...

Accumetrics, Inc. Announces 1000th Patient Enrolled in GRAVITAS Trial

...o controlled trial will determine whether tailored antiplatelet therapy for poor responders, identified based on t...hat patients receive not only the most appropriate antiplatelet therapy, but also the adequate dose," said Jeff Da...VITAS The concept of variability in response to antiplatelet therapy has been well established. The question of...

Antiplatelet in Medical Technology

Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use

Leading Medical Associations Collaborate to Improve Patient Safety WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- The American College of Cardiology in collaboration with the American College of Gastroenterology and the American Heart Association today released consensus guidelines outlining ...

FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel

Companies confirm the start of TRILOGY ACS clinical trial to study Prasugrel against Clopidogrel in medically managed ACS patients TOKYO and INDIANAPOLIS, June 23 /PRNewswire-FirstCall/ -- Daiichi Sankyo Company, Limited, (TSE:4568) and Eli Lilly and Company (NYSE: LLY ) said that the U...

New Data Show High Frequency of Medical Claims for Gastrointestinal Events by Patients on Antiplatelet Therapy

Review of Insurance Claims Tracked Ulcers and Bleeding Among 368,000 Patients Prescribed Clopidogrel TORONTO, May 6 /PRNewswire/ -- A review of medical claims from more than 70 managed care plans showed that 6.2 percent of patients prescribed the antiplatelet medicine clop...

Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168

MENLO PARK, Calif., Jan. 16 /PRNewswire/ -- Cogentus Pharmaceuticals, Inc. today announced that dosing has begun in a clinical study to confirm the full antiplatelet activity of its novel combination medicine CGT-2168. CGT-2168 is a once-daily capsule that combines clopidogrel (currently marke...

Cogentus to Launch Phase III Program of Novel Combination Product Designed to Reduce Bleeding Side Effect of Antiplatelet Therapy

COGENT Trials To Enroll 4,000 Patients Worldwide MENLO PARK, Calif., Nov. 15 /PRNewswire/ -- Cogentus Pharmaceuticals, Inc. announced today it is launching a global Phase III clinical program to evaluate the efficacy and safety of its novel combination therapy CGT-2168. The program...

SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients

Inhibition Was Sustained and Dose-Dependent in Sub-Analysis of Phase II TRA- PCI Trial ORLANDO, Fla., Nov. 7 /PRNewswire-FirstCall/ -- SCH 530348 (TRA), the novel investigational antiplatelet agent in development by Schering-Plough Corporation (NYSE: SGP ), was sho...

deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia

...ntion of common diseases. Its lead therapeutic programs, which leverage the company's expertise in chemistry and structural biology, include DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of...

Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled

...o controlled trial will determine whether tailored antiplatelet therapy for poor responders, identified based on t...wn to be an integral tool in optimizing the use of antiplatelet therapy." About GRAVITAS The concept of variability in response to antiplatelet therapy has been well established. Also being dem...

Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents

...s from 4.2% to 5.3%, with another event occurring at 658 days in a patient who had previously presented with a subacute thrombosis and who was on dual antiplatelet therapy at the time of both thromboses. There were no thrombotic events in the Genous treated group at any time period (0.0%). Myocardial infarction...

New Studies Show Popular Heartburn Medications Moderate the Effect of Taking Widely Prescribed Heart Drug

...benefit associated with clopidogrel, a widely used antiplatelet medication also known by its brand name, Plavix. T...intestinal bleeding, a possible side-effect of the antiplatelet drug. While 41 percent of patients in the study w...d clopidogrel and impairs the effectiveness of the antiplatelet drug," said Epstein. "Given the totality of the e...

Antiplatelet in Medical Products

VerifyNow System

Description:...to aspirin ingestion. The GP IIb/IIIa inhibitor class of intravenous antiplatelet agents, has demonstrated benefit in treating patients undergoing coronary i...ates that over 2.5 million patients annually are candidates for intravenous antiplatelet therapy. Data from clinical trials suggest that both the safety and efficac...
Company:Accumetrics

Just the Facts in Emergency Medicine

Features:...rption of material Includes special sections that review the various written exams and provide text-taking tips and strategies Provides information on antiplatelet agents, pain management, stroke management and new treatments for virial disorders ...
Company:USBMIS Inc.

Antiplatelet in Biological News

American Chemical Society's weekly PressPac -- May 27, 2009

...icles "hold immense potential to be promoted as an antiplatelet agent," the researchers note. "Nanosilver appears ...elpful to the health of mankind antibacterial and antiplatelet which together can have unique utilities, for exa...CLE #2 FOR IMMEDIATE RELEASE "Characterization of antiplatelet Properties of Silver Nanoparticles" DOWNLOAD FU...

12-month ATLANTA trial data show sustained benefit of Catania Stent

...ity reactions, as well as the economic impact of maintaining long-term dual antiplatelet therapy," said Corrado Tamburino, MD, PhD, FESC, FSCAI, FSICI-GISE, Profess...s merit, because it does away with the costs associated with long-term dual antiplatelet therapy." The rapid-exchange, cobalt-chromium CATANIA™ stent carri...

Access to existing medical treatments could save more lives than spending to improve the treatments

...he point. They used two case studies -- one involving statins and the other antiplatelet drugs -- to show that the billions of dollars spent on new generation drugs...re strokes than were prevented by developing more potent and more expensive antiplatelet drugs, Woolf said. In another example, Woolf and Johnson estimate that for...

NIH renews network focused on how genes influence drug responses

...s (arrhythmias) are beneficial to some people and harmful to others. (Dan M. Roden, M.D., Vanderbilt University) The Amish Pharmacogenomics of antiplatelet Intervention Study --$7.5 million provided by NIGMS to characterize the genetic basis for why people respond differently to medicines, including aspi...

Antiplatelet in Biological Technology

Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration

If Approved for Marketing in the United States, Trade Name Will be Effient(TM) TOKYO and INDIANAPOLIS, Jan. 4 /PRNewswire-FirstCall/ -- Daiichi Sankyo Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: LLY ) today announced that on Wednesday, Dec. 26...

Regado Biosciences Expands Medical Advisory Board

... and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics, including anticoagulants and antiplatelet agents, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's tec...

It's Not Just the Sun: deCODE Discovers Sequence Variants Affecting Susceptibility to Skin Cancer

...ntion of common diseases. Its lead therapeutic programs, which leverage the company's expertise in chemistry and structural biology, include DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of...

deCODE Discovers a Gene Linked to Risk of Kidney Stones and Osteoporosis

...ntion of common diseases. Its lead therapeutic programs, which leverage the company's expertise in chemistry and structural biology, include DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of...

deCODE Reinstated to Nasdaq Global Market

...ntion of common diseases. Its lead therapeutic programs, which leverage the company's expertise in chemistry and structural biology, include DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of...

Accumetrics, Inc. Announces European Distribution Channels for France, Austria, Switzerland, Netherlands, Belgium and Luxembourg

... VerifyNow System assesses response to life-saving antiplatelet therapies, such as aspirin, Plavix(R) and GP IIb/...the tests help physicians ensure their patients on antiplatelet medications are receiving the optimal benefit. ...tion for managing their cardiovascular patients on antiplatelet therapies." A b ou t A ccu m e tr...

Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial

...Company (NYSE: LLY ) are co-developing prasugrel, an investigational oral antiplatelet agent invented by Daiichi Sankyo and its Japanese research partner Ube Indu...ing the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. antiplatelet agents prevent platelets from clumping or sticking together, which can resu...

deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation

...ntion of common diseases. Its lead therapeutic programs, which leverage the company's expertise in chemistry and structural biology, include DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of...

deCODE Study Shows Complex Interplay of the Human Biological Clock With Height, Weight and Disease

...ntion of common diseases. Its lead therapeutic programs, which leverage the company's expertise in chemistry and structural biology, include DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of...

deCODE genetics Announces First Quarter 2009 Financial Results

...ntion of common diseases. Its lead therapeutic programs, which leverage the company's expertise in chemistry and structural biology, include DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of...